

Author Index Volume 23 (2014/2015)

The issue number is given in front of the pagination

- Abdolalizadeh, J., see Ezzatifar, F. (1,2) 7–12
Adias, T.C., see Okwesili, A.N. (3,4) 57–62
Ahmed, M.H., see Okwesili, A.N. (3,4) 57–62
Alinejad, V., see Sadreddini, S. (3,4) 73–79
- Baradaran, B., J. Majidi, S. Farajnia, J. Barar and Y. Omidi, Targeted therapy of solid tumors by monoclonal antibody specific to epidermal growth factor receptor (1,2) 13–20
Baradaran, B., see Ezzatifar, F. (1,2) 7–12
Barar, J., see Baradaran, B. (1,2) 13–20
Barzilai, O., see Sagi, L. (1,2) 27–30
Baum, S., see Sagi, L. (1,2) 27–30
Bizzaro, N., see Sagi, L. (1,2) 27–30
Buhari, H., see Okwesili, A.N. (3,4) 57–62
- Depicker, A., see Viridi, V. (3,4) 37–43
- Eftekharian, M.M., M. Mousavi, M.B. Hormoz, G. Roshanaei and M. Mazdeh, Multiple sclerosis and immunological-related risk factors: Results from a case-control study (1,2) 31–36
Erhabor, O., see Okwesili, A.N. (3,4) 57–62
Ezzatifar, F., J. Majidi, B. Baradaran, L.A. Maleki, J. Abdolalizadeh and M. Yousefi, Development and characterization of monoclonal antibodies against human IgA in Balb/c mice (1,2) 7–12
- Farajnia, S., see Baradaran, B. (1,2) 13–20
Fatemeh, R., see Naseri, M. (1,2) 1–5
- Ghasemi, B., see Sadreddini, S. (3,4) 73–79
- Hiatt, A., M. Pauly, K. Whaley, X. Qiu, G. Kobinger and L. Zeitlin, The emergence of antibody therapies for Ebola (3,4) 49–56
Hormoz, M.B., see Eftekharian, M.M. (1,2) 31–36
- Ibrahim, A., see Okwesili, A.N. (3,4) 57–62
- Ibrahim, K., see Okwesili, A.N. (3,4) 57–62
Isaac, Z., see Okwesili, A.N. (3,4) 57–62
- Jadidi-Niaragh, F., see Sadreddini, S. (3,4) 73–79
Jafaru, H., see Okwesili, A.N. (3,4) 57–62
Juarez, P., see Viridi, V. (3,4) 37–43
- Kafil, H.S., see Sadreddini, S. (3,4) 73–79
Kallolimath, S. and H. Steinkellner, Glycosylation of plant produced human antibodies (3,4) 45–48
Khan, A.H. and E. Sadroddiny, Licensed monoclonal antibodies and associated challenges (3,4) 63–72
Kobinger, G., see Hiatt, A. (3,4) 49–56
- Mahdavi, M., see Nejad, H.R. (1,2) 21–26
Mainasara, M.Y., see Okwesili, A.N. (3,4) 57–62
Majidi, J., see Baradaran, B. (1,2) 13–20
Majidi, J., see Ezzatifar, F. (1,2) 7–12
Maleki, L.A., see Ezzatifar, F. (1,2) 7–12
Mazdeh, M., see Eftekharian, M.M. (1,2) 31–36
Mehrabadi, J.F., see Nejad, H.R. (1,2) 21–26
Moazzeni, M., see Naseri, M. (1,2) 1–5
Mousavi, M., see Eftekharian, M.M. (1,2) 31–36
- Naseri, M., M. Moazzeni, A.A. Pourfathollah and R. Fatemeh, Determination of dissociation constants of Anti-ALP monoclonal antibodies by an ELISA – based method (1,2) 1–5
Nejad, H.R., J.F. Mehrabadi, J. Nourozi and M. Mahdavi, Construction of scFv library of human antibodies against tetanus toxin (1,2) 21–26
Nourozi, J., see Nejad, H.R. (1,2) 21–26
- Okwesili, A.N., F.U. Onuigwe, K. Ibrahim, H. Buhari, A. Ibrahim, H. Jafaru, O. Erhabor, F.U. Onuigwe, Z. Isaac, M.H. Ahmed, M.Y. Mainasara, T.C. Adias, M.H. Yeldu, E.K. Uko and F. Udoma, Prevalence of Hepatitis B surface antigen among biomedical students of African descent in Usmanu Danfodiyo University, Sokoto, Nigeria (3,4) 57–62

- Omidi, Y., see Baradaran, B. (1,2) 13–20
Onuigwe, F.U., see Okwesili, A.N. (3,4) 57–62
Onuigwe, F.U., see Okwesili, A.N. (3,4) 57–62
- Pauly, M., see Hiatt, A. (3,4) 49–56
Pourfathollah, A.A., see Naseri, M. (1,2) 1–5
- Qiu, X., see Hiatt, A. (3,4) 49–56
- Ram, M., see Sagi, L. (1,2) 27–30
Roshanaei, G., see Eftekharian, M.M. (1,2) 31–36
- Sadreddini, S., M. Seifi-Najmi, B. Ghasemi, H.S. Kafil, V. Alinejad, S. Sadreddini, V. Younesi, F. Jadidi-Niaragh and M. Yousefi, Design and construction of immune phage antibody library against Tetanus neurotoxin: Production of single chain antibody fragments (3,4) 73–79
Sadreddini, S., see Sadreddini, S. (3,4) 73–79
Sadroddiny, E., see Khan, A.H. (3,4) 63–72
Sagi, L., S. Baum, O. Barzilai, M. Ram, N. Bizzaro, M. SanMarco, Y. Shoenfeld and Y. Sherer, Novel antiphospholipid antibodies in autoimmune bullous diseases (1,2) 27–30
SanMarco, M., see Sagi, L. (1,2) 27–30
Seifi-Najmi, M., see Sadreddini, S. (3,4) 73–79
Sherer, Y., see Sagi, L. (1,2) 27–30
Shoenfeld, Y., see Sagi, L. (1,2) 27–30
Steinkellner, H., see Kallolimath, S. (3,4) 45–48
- Udoma, F., see Okwesili, A.N. (3,4) 57–62
Uko, E.K., see Okwesili, A.N. (3,4) 57–62
- Virdi, V., P. Juarez and A. Depicker, Plant expression systems for early stage discovery and development of lead therapeutic antibodies (3,4) 37–43
- Whaley, K., see Hiatt, A. (3,4) 49–56
- Yeldu, M.H., see Okwesili, A.N. (3,4) 57–62
Younesi, V., see Sadreddini, S. (3,4) 73–79
Yousefi, M., see Ezzatifar, F. (1,2) 7–12
Yousefi, M., see Sadreddini, S. (3,4) 73–79
- Zeitlin, L., see Hiatt, A. (3,4) 49–56